Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Recent publications published by researchers at the MRC WIMM.

Development of a Recombinant Single-Cycle Influenza Viral Vector as an Intranasal Vaccine against SARS-CoV-2 and SARS-like Betacoronaviruses.

Munro J. et al, (2025)

A locally administered single-cycle influenza vaccine expressing a non-fusogenic stabilized hemagglutinin stimulates strong T-cell and neutralizing antibody immunity.

Sadler HL. et al, (2025), J Virol, 99

The molecular reach of antibodies crucially underpins their viral neutralisation capacity.

Huhn A. et al, (2025), Nat Commun, 16

Proactive vaccination using multiviral Quartet Nanocages to elicit broad anti-coronavirus responses.

Hills RA. et al, (2024), Nat Nanotechnol, 19, 1216 - 1223

Publisher Correction: Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells.

Barnkob MB. et al, (2024), Nat Commun, 15

Semmaphorin 3 A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells.

Barnkob MB. et al, (2024), Nat Commun, 15

A locally administered single cycle influenza vaccine expressing a non-fusogenic stabilised haemagglutinin stimulates strong T-cell and neutralising antibody immunity

Sadler H. et al, (2024)

Changes in population immunity to omicron SARS-CoV-2 variants and selected Sarbecoviruses from 2020 to 2023 in urban Colombo, Sri Lanka

Bary F. et al, (2024)

Single-cycle influenza virus vaccine generates lung CD8+ Trm that cross-react against viral variants and subvert virus escape mutants.

Zheng MZM. et al, (2023), Sci Adv, 9

Multiviral Quartet Nanocages Elicit Broad Anti-Coronavirus Responses for Proactive Vaccinology.

Hills RA. et al, (2023), bioRxiv

Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.

Huang K-YA. et al, (2023), Nat Commun, 14

Analysis of emergent bivalent antibody binding identifies the molecular reach as a critical determinant of SARS-CoV-2 neutralisation potency

Huhn A. et al, (2023)

The magnitude and cross reactivity of SARS-CoV-2 specific antibody responses in vaccinated and unvaccinated Sri Lankan children and association with nutrition status

Jeewandara C. et al, (2023)

Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8+ T Cells in the Face of Pre-Existing Humoral Immunity.

Zheng MZM. et al, (2022), J Immunol, 209, 1832 - 1836

Cutting Edge: High-Dose Live Attenuated Influenza Vaccines Elicit Pulmonary Tissue-Resident Memory CD8+ T Cells in the Face of Pre-Existing Humoral Immunity.

Zheng MZM. et al, (2022), J Immunol

Secondary influenza challenge triggers resident memory B cell migration and rapid relocation to boost antibody secretion at infected sites.

MacLean AJ. et al, (2022), Immunity, 55, 718 - 733.e8

Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models.

Cohen AA. et al, (2022), bioRxiv

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Dejnirattisai W. et al, (2021)

Immune Responses to a Single Dose of the AZD1222/Covishield Vaccine at 16 Weeks in Individuals in Sri Lanka.

Jeewandara C. et al, (2021), J Immunol, 207, 2681 - 2687

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Skelly DT. et al, (2021), Nat Commun, 12

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?